New CAR t-cell combo aims to control aggressive leukemia
NCT ID NCT06287229
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study tests a CAR T-cell drug called brexucabtagene autoleucel in 40 adults with B-cell acute lymphocytic leukemia that has come back or is hard to treat. Participants first receive standard chemotherapy drugs to reduce cancer, then get the CAR T-cells. The goal is to see if this approach safely controls the disease. The study is recruiting now.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cheaper copy of a leukemia drug work just as well?
- Engineered immune cells take aim at returning blood cancers
- Engineered immune cells take aim at tough childhood cancers
- Experimental CAR-T therapy takes on stubborn blood disorder
- Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse
- Off-the-Shelf CAR-T cells take on tough leukemia in early trial